Otros

<p>Impurity Entacapone EP Impurity A<br>Applications cis-Entacapone (Entacapone EP Impurity A) is the (Z)-Isomer of Entacapone polymorphic form B. Antiparkinsonian.<br>References Karlsson, M., et al.: J. Pharm. Biomed. Anal., 10, 593 (1992), Nissinen, E., et al.: Arch. Pharmacol., 346, 262 (1992), Wikberg, T., et al.: Eur. J. Drug Metab. Pharmacokinet., 18, 359 (1993),<br></p>

<p>Applications The main metabolite of Entacapone and Tolcapone.<br>References Mannisto, P., et al.: Prog. Drug Res., 39, 291(1992), Nishi, H., et al.: J. Pharm. Biomed. Anal., 11, 1277 (1993), Wikberg, T., et al.: Eur. J. Drug Metab. Pharmacokinet., 18, 359 (1993),<br></p>

<p>Applications Isotope labelled MDV 3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis, and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer.<br></p>

<p>Impurity Lorazepam USP Related Compound A<br>Stability hygroscopic<br>Applications Lorazepam is an anxiolytic compound that potentiates GABAergic synaptic transmission by binding at the benzodiazepine site on the GABAA receptor.1,2 This product is intended for forensic and research applications. Lorazepam acts as ananticonvulsant. Lorazepam USP Related Compound A.Controlled substance (depressant).<br>References Rutgers, G., et al.: Anal. Profiles Drug Subs., 9, 397 (1980), Korkmaz, S., et al.: Eur. Neuropsychopharmacol., 8, 175 (1998), D’Onofrio, G., et al.: N. Engl. J. Med., 340, 915 (1999),<br></p>

<p>Applications Aryl-oxymethyl analog of prostaglandin F2α.<br>References Binder, D., et al.: Prostaglandins, 6, 87 (1974), Bourne, G.R., et al.: Xenobiotica, 9, 623 (1979), Baishya, N., et al.: Br. Vet. J., et al.: 136, 227 (1980), Whyman, D., et al.: J. Reprod. Fertil., 60, 267 (1980),<br></p>